A Phase 1b Dose Escalation Safety Analysis of Lenalidomide and Azacitidine Maintenance Therapy for Poor Risk AML

被引：0
|
作者：
Wei, Andrew H. [1 ]
Tan, Peter T. [2 ]
Walker, Patricia A. [2 ]
Avery, Sharon [2 ]
Patil, Sushrut S. [2 ]
Schwarer, Anthony P. [2 ]
Januszewicz, Elchanan H. [3 ]
Harrison, Simon J. [3 ]
Ho, Wai Khoon [4 ]
Tam, Constantine S. [5 ]
Spencer, Andrew
机构：
[1] Monash Univ, Alfred Hosp, Melbourne, Vic 3181, Australia
[2] Alfred Hosp, Dept Clin Haematol, Melbourne, Vic, Australia
[3] Peter MacCallum Canc Ctr, Dept Haematol & Oncol, Melbourne, Australia
[4] Austin Hlth, Dept Haematol, Melbourne, Australia
[5] St Vincents Hosp, Dept Haematol, Sydney, NSW, Australia
来源：
BLOOD | 2011年 / 118卷 / 21期
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页码：1548 / 1549
页数：2
相关论文
共 50 条
  • [1] Phase 1b Dose Escalation Study of BI 836858 and Azacitidine in Previously Untreated AML: Results from Beat AML S2
    Blum, William
    Ruppert, Amy S.
    Mims, Alice S.
    Stein, Eytan M.
    Duong, Vu H.
    Odenike, Olatoyosi
    Patel, Prapti A.
    Kovacsovics, Tibor
    Heerema, Nyla A.
    Vergilio, Jo-Anne
    Rosenberg, Leonard
    Marcus, Sonja
    Stefanos, Mona
    Weiner, Howard
    Brandt, Jake
    Shoben, Abigail
    Druker, Brian J.
    Burd, Amy
    Levine, Ross L.
    Byrd, John C.
    Borate, Uma
    BLOOD, 2018, 132
  • [2] Lemzoparlimab (lemzo) with venetoclax (ven) and/or azacitidine (aza) in patients (pts) with acute myeloid leukemia (AML) or myelodysplastic syndromes (MDS): A phase 1b dose escalation study.
    Daver, Naval Guastad
    Stevens, Don A.
    Hou, Jing-Zhou
    Yamauchi, Takahiro
    Moshe, Yakir
    Fong, Chun Yew
    Marzocchetti, Angela
    Adamec, Ryan
    Patel, Maulik
    Lambert, Stacie
    Wu, Kevin
    Rollig, Christoph
    JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (16)
  • [3] A phase 1 study of concomitant high-dose lenalidomide and 5-azacitidine induction in the treatment of AML
    Ramsingh, G.
    Westervelt, P.
    Cashen, A. F.
    Uy, G. L.
    Stockerl-Goldstein, K.
    Abboud, C. N.
    Bernabe, N.
    Monahan, R.
    DiPersio, J. F.
    Vij, R.
    LEUKEMIA, 2013, 27 (03) : 725 - 728
  • [4] A phase 1 study of concomitant high-dose lenalidomide and 5-azacitidine induction in the treatment of AML
    G Ramsingh
    P Westervelt
    A F Cashen
    G L Uy
    K Stockerl-Goldstein
    C N Abboud
    N Bernabe
    R Monahan
    J F DiPersio
    R Vij
    Leukemia, 2013, 27 : 725 - 728
  • [5] Sequential Azacitidine and High-Dose Lenalidomide for Relapsed and Refractory High-Risk MDS and AML: Interim Analysis of a Phase 2 Study
    Pollyea, Daniel A.
    Smith, Clayton A.
    Nguyen, Vu H.
    Fullerton, Aaron
    Schatz, Derek
    Bedrick, Edward J.
    Gutman, Jonathan A.
    BLOOD, 2014, 124 (21)
  • [6] Safety and Efficacy of Combining Tagraxofusp (SL-401) with Azacitidine or Azacitidine and Venetoclax in a Phase 1b Study for CD123 Positive AML, MDS, or BPDCN
    Lane, Andrew A.
    Stein, Anthony S.
    Garcia, Jacqueline S.
    Garzon, Jada L.
    Galinsky, Ilene
    Luskin, Marlise R.
    Stone, Richard M.
    Winer, Eric S.
    Leonard, Rebecca
    Mughal, Tariq I.
    Brooks, Christopher L.
    Konopleva, Marina
    Stevenson, Kristen E.
    Pemmaraju, Naveen
    BLOOD, 2021, 138
  • [7] Final Analysis of a Phase II Study of Intrapatient Dose-Escalation of Eltrombopag in Patients Receiving Azacitidine for Myelodysplasia/AML
    Dickinson, Michael J.
    Herbert, Kirsten
    Sardjono, Caroline
    Thao Le
    Zannino, Diana
    Wood, Colin
    Seymour, John F.
    Kenealy, Melita
    Prince, Miles
    BLOOD, 2014, 124 (21)
  • [8] Multicenter Phase 1b Dose-Escalation Study of Ibrutinib and Lenalidomide Combined with Dose-Adjusted EPOCH-R in Patients with Relapsed/Refractory DLBCL
    Wilson, Wyndham H.
    Popplewell, Leslie L.
    Phillips, Tycel
    Kimball, Amy S.
    Chhabra, Saurabh
    Ping, Jerry
    Neuenburg, Jutta
    Cavazos, Nora
    Staudt, Louis M.
    de Vos, Sven
    BLOOD, 2015, 126 (23)
  • [9] Results of the safety and tolerability of ivaltinostat plus capecitabine in the phase 1b portion of a phase 1b/2, dose-escalation, randomized, multi-center study in the maintenance (maint) setting in patients with metastatic pancreatic adenocarcinoma (mPDAC).
    Walker, Evan Justin
    Fountzilas, Christos
    Borazanci, Erkut Hasan
    Shields, Anthony F.
    D'Olimpio, James Thomas
    Hecht, J. Randolph
    Tang, Shou-Ching
    Michelson, Glenn
    Liganor, Lorna
    Cho, Sangsook Ahn
    Ko, Andrew H.
    JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (3_SUPPL) : 666 - 666
  • [10] Results of the Phase 1b Dose Escalation Study of OPB-111077, Decitabine, and Venetoclax for the Treatment of Newly Diagnosed or Relapsed/Refractory AML
    Wilde, Lindsay
    Martinez-Outschoorn, Ubaldo
    Palmisiano, Neil
    Keiffer, Gina
    Kasner, Margaret
    BLOOD, 2020, 136
12345